These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32316084)

  • 1. Loxoscelism: Advances and Challenges in the Design of Antibody Fragments with Therapeutic Potential.
    Karim-Silva S; Becker-Finco A; Jiacomini IG; Boursin F; Leroy A; Noiray M; de Moura J; Aubrey N; Billiald P; Alvarenga LM
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32316084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism.
    Karim-Silva S; Moura Jd; Noiray M; Minozzo JC; Aubrey N; Alvarenga LM; Billiald P
    Immunol Lett; 2016 Aug; 176():90-6. PubMed ID: 27288291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic characterization, antigenic cross-reactivity and neutralization of dermonecrotic activity of five Loxosceles spider venoms of medical importance in the Americas.
    Barbaro KC; Knysak I; Martins R; Hogan C; Winkel K
    Toxicon; 2005 Mar; 45(4):489-99. PubMed ID: 15733571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous loxoscelism caused by Loxosceles similis venom and neutralization capacity of its specific antivenom.
    Chatzaki M; Horta CC; Almeida MO; Pereira NB; Mendes TM; Dias-Lopes C; Guimarães G; Moro L; Chávez-Olórtegui C; Horta MC; Kalapothakis E
    Toxicon; 2012 Jul; 60(1):21-30. PubMed ID: 22465492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of dermonecrotic and lethal activities and differences among 32-35 kDa toxins of medically important Loxosceles spider venoms in Brazil revealed by monoclonal antibodies.
    Guilherme P; Fernandes I; Barbaro KC
    Toxicon; 2001 Sep; 39(9):1333-42. PubMed ID: 11384721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of monoclonal antibodies capable of neutralizing dermonecrotic activity of Loxosceles intermedia spider venom and their use in a specific immunometric assay.
    Alvarenga LM; Martins MS; Moura JF; Kalapothakis E; Oliveira JC; Mangili OC; Granier C; Chávez-Olórtegui C
    Toxicon; 2003 Dec; 42(7):725-31. PubMed ID: 14757202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodetection of the "brown" spider (Loxosceles intermedia) dermonecrotoxin with an scFv-alkaline phosphatase fusion protein.
    Jiacomini I; Silva SK; Aubrey N; Muzard J; Chavez-Olortegui C; De Moura J; Billiald P; Alvarenga LM
    Immunol Lett; 2016 May; 173():1-6. PubMed ID: 26970375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against dermonecrotic and lethal activities of Loxosceles intermedia spider venom by immunization with a fused recombinant protein.
    Araujo SC; Castanheira P; Alvarenga LM; Mangili OC; Kalapothakis E; Chávez-Olórtegui C
    Toxicon; 2003 Mar; 41(3):261-7. PubMed ID: 12565747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG antibodies to Loxosceles sp. spider venom in human envenoming.
    Barbaro KC; Cardoso JL; Eickstedt VR; Mota I
    Toxicon; 1992 Sep; 30(9):1117-21. PubMed ID: 1440649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protective vaccine against the toxic activities following Brown spider accidents based on recombinant mutated phospholipases D as antigens.
    Polli NLC; Justa HCD; Antunes BC; Silva TPD; Dittrich RL; de Souza GS; Wille ACM; Matsubara FH; Minozzo JC; Mariutti RB; Arni RK; Senff-Ribeiro A; Veiga SS; Gremski LH
    Int J Biol Macromol; 2021 Dec; 192():757-770. PubMed ID: 34634338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Protein Containing B-Cell Epitopes of Different
    Lima SA; Guerra-Duarte C; Costal-Oliveira F; Mendes TM; Figueiredo LFM; Oliveira D; Machado de Avila RA; Ferrer VP; Trevisan-Silva D; Veiga SS; Minozzo JC; Kalapothakis E; Chávez-Olórtegui C
    Front Immunol; 2018; 9():653. PubMed ID: 29666624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the understanding of brown spider venoms: From the biology of spiders to the molecular mechanisms of toxins.
    Gremski LH; Trevisan-Silva D; Ferrer VP; Matsubara FH; Meissner GO; Wille AC; Vuitika L; Dias-Lopes C; Ullah A; de Moraes FR; Chávez-Olórtegui C; Barbaro KC; Murakami MT; Arni RK; Senff-Ribeiro A; Chaim OM; Veiga SS
    Toxicon; 2014 Jun; 83():91-120. PubMed ID: 24631373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a common epitope in knottins and phospholipases D present in Loxosceles sp venom by a monoclonal antibody.
    Alves-Mondini C; Beltramino M; Jiacomini IG; Karim-Silva S; Dos Santos Antunes N; de Moura J; Aubrey N; Billiald P; Machado-de-Ávila RA; Alvarenga LM; Becker-Finco A
    Int J Biol Macromol; 2023 Aug; 246():125588. PubMed ID: 37399872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of the neutralizing capacity of horse antivenom against the Brazilian spider Loxosceles intermedia.
    Braz A; Minozzo J; Abreu JC; Gubert IC; Chávez-Olórtegui C
    Toxicon; 1999 Sep; 37(9):1323-8. PubMed ID: 10400292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative Immunization Strategies for Antivenom Development.
    Bermúdez-Méndez E; Fuglsang-Madsen A; Føns S; Lomonte B; Gutiérrez JM; Laustsen AH
    Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30400220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered antigen containing epitopes from Loxosceles spp. spider toxins induces a monoclonal antibody (Lox-mAb3) against astacin-like metalloproteases.
    Costa TGF; Costal-Oliveira F; de Assis TCS; Lima SA; Martins CA; Finco AB; Veiga SS; Soccol VT; Machado-de-Ávila RA; Figueiredo LFM; Minozzo JC; Kalapothakis E; Guerra-Duarte C; Alvarenga LM; Chávez-Olórtegui C
    Int J Biol Macromol; 2020 Nov; 162():490-500. PubMed ID: 32574737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brown spider (Loxosceles genus) venom toxins: Evaluation of biological conservation by immune cross-reactivity.
    Buch DR; Souza FN; Meissner GO; Morgon AM; Gremski LH; Ferrer VP; Trevisan-Silva D; Matsubara FH; Boia-Ferreira M; Sade YB; Chaves-Moreira D; Gremski W; Veiga SS; Chaim OM; Senff-Ribeiro A
    Toxicon; 2015 Dec; 108():154-66. PubMed ID: 26474948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and molecular characterization of a monoclonal antibody reactive with conserved epitope in sphingomyelinases D from Loxosceles spider venoms.
    Dias-Lopes C; Felicori L; Rubrecht L; Cobo S; Molina L; Nguyen C; Galéa P; Granier C; Molina F; Chávez-Olortegui C
    Vaccine; 2014 Apr; 32(18):2086-92. PubMed ID: 24565754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning and expression of a functional dermonecrotic and haemolytic factor from Loxosceles laeta venom.
    Fernandes Pedrosa Mde F; Junqueira de Azevedo Ide L; Gonçalves-de-Andrade RM; van den Berg CW; Ramos CR; Ho PL; Tambourgi DV
    Biochem Biophys Res Commun; 2002 Nov; 298(5):638-45. PubMed ID: 12419302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative immunization protocols using chimeric recombinant protein for the production of polyspecific loxoscelic antivenom in horses.
    Figueiredo LF; Dias-Lopes C; Alvarenga LM; Mendes TM; Machado-de-Ávila RA; McCormack J; Minozzo JC; Kalapothakis E; Chávez-Olórtegui C
    Toxicon; 2014 Aug; 86():59-67. PubMed ID: 24878371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.